… -DOTATATE 230 Progressive, SSTR+ midgut NETs 8.4 mo vs NR 3% vs 18% Strosberg
2017113 … Jonathan R. Strosberg has consulted for Novartis and has received speaking fees from …

Gastroenteropancreatic (GEP) neuroendocrine neoplasms are classified as low‐grade,
intermediate‐grade, and high‐grade tumors based on morphologic criteria and the proliferation …

Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the
past decades, and are now the most common type of small bowel tumor. Consequently, …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …

BACKGROUND. Temozolomide is an active agent in metastatic pancreatic endocrine
carcinomas. In vitro data indicate that the combination of capecitabine and temozolomide is …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Background Effective systemic therapies for patients with advanced, progressive neuroendocrine
tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy …

Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide versus …

… Jonathan R. Strosberg is a consultant for Novartis and Pfizer, receives grant funding from
Genentech and Novartis, and receives honorarium from Genentech, Pfizer and Sanofi. …

Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be
associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical …